Circular Genomics and Altoida are combining a blood-based circular RNA biomarker assay with an AI-driven digital cognitive assessment to build a two-step screening pathway for Alzheimer's disease. The circRNA signature, published in Nature Medicine, predicts progression to symptomatic disease years before clinical onset, while the digital assessment detects mild cognitive impairment without specialist involvement. Earlier and more accurate identification of preclinical neurodegeneration widens the window in which modifiable risk factors and emerging therapeutics can still alter trajectory.
Key Points
- Blood circRNA signature predicts Alzheimer's progression years before symptoms appear
- Digital cognitive testing screens first, blood assay confirms molecular risk
- Digital NeuroMarker remains investigational; pivotal FDA clearance study in preparation
Longevity Analysis
Cognitive decline is typically identified after functional loss is already established, by which point intervention options narrow considerably. Pairing a molecular readout circulating in blood with objective measures of attention, memory and motor function creates a far earlier and more interpretable signal from a system that otherwise communicates its deterioration slowly and ambiguously. Detection at the preclinical stage is what makes upstream work meaningful — sleep architecture, vascular health, metabolic control, inflammatory load and removal of neurotoxic exposures all carry more weight when applied before neuronal loss accumulates.
Original published by Longevity.Technology.